Literature DB >> 7605592

Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease.

M Mogi1, M Harada, T Kondo, P Riederer, T Nagatsu.   

Abstract

beta 2-Microglobulin (B2-MG) content was measured for the first time in the brain (caudate nucleus, putamen, and cerebral cortex) from control and parkinsonian patients by a highly sensitive sandwich enzyme immunoassay. The concentrations of B2-MG in dopaminergic striatal regions were significantly higher in parkinsonian patients than those in controls, whereas those in the cerebral cortex showed no significant difference between parkinsonian and control subjects. Tumor necrosis factor-alpha (TNF-alpha) concentrations were also increased in the striatum, confirming our previous findings, but not in the cerebral cortex. Since TNF-alpha may induce B2-MG expression, these results suggest that an immunological response may occur in the nigrostriatal dopaminergic regions in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605592     DOI: 10.1007/BF02252965

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  27 in total

1.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

2.  Astrocyte-neuron interactions in neurological disorders.

Authors:  G Ricci; L Volpi; L Pasquali; L Petrozzi; G Siciliano
Journal:  J Biol Phys       Date:  2009-05-14       Impact factor: 1.365

3.  Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication.

Authors:  M Mogi; M Harada; T Kondo; P Riederer; T Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

Review 5.  Inflammation as a causative factor in the aetiology of Parkinson's disease.

Authors:  P S Whitton
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

Review 6.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

7.  Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Authors:  Melanie B Watson; Franziska Richter; Soo Kyung Lee; Lauryn Gabby; Jennifer Wu; Eliezer Masliah; Rita B Effros; Marie-Françoise Chesselet
Journal:  Exp Neurol       Date:  2012-06-27       Impact factor: 5.330

Review 8.  Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.

Authors:  Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-08       Impact factor: 3.575

Review 9.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.